Home Biosimilar Antibodies Transmembrane Transporters Others Glembatumumab vedotin
For research use only. Not for use in humans.

Glembatumumab vedotin

Synonyms: CDX-011 (DOX), CR011,CR011-vcMMAE

Glembatumumab vedotin (CDX-011 (DOX), CR011,CR011-vcMMAE) is an antibody-drug conjugate (ADC) composed of an fully human IgG2 monoclonal antibody (CR011) directed against glycoprotein NMB (GPNMB), conjugated to Monomethyl Auristatin E (MMAE), via a cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. Glembatumumab vedotin has the potential for use in research of Breast cancer (TNBC) and advanced or metastatic melanoma.

Glembatumumab vedotin

CAS No. 1182215-65-1

Click to purchase products related to Glembatumumab vedotin

Quality Control

Batch: Purity: 99% Protein concentration: 3.42 mg/ml Endotoxin Level: ＜1EU/mg
99

Mechanism of Action

Description
Glembatumumab vedotin (CDX-011 (DOX), CR011,CR011-vcMMAE) is an antibody-drug conjugate (ADC) composed of an fully human IgG2 monoclonal antibody (CR011) directed against glycoprotein NMB (GPNMB), conjugated to Monomethyl Auristatin E (MMAE), via a cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. Glembatumumab vedotin has the potential for use in research of Breast cancer (TNBC) and advanced or metastatic melanoma.
References

Product Details

CAS No. 1182215-65-1
ADC antiody Glembatumumab
ADC cytotoxin MMAE
Formulation 1xPBS
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02363283 COMPLETED Drug: Glembatumumab Vedotin Recurrent Uveal Melanoma; Stage IV Uveal Melanoma AJCC v7 National Cancer Institute (NCI) 2015-09-16 PHASE2
NCT02302339 TERMINATED Drug: glembatumumab vedotin|Drug: glembatumumab vedotin and Melanoma Celldex Therapeutics 2014-11 PHASE2
NCT02713828 TERMINATED Drug: Phase I: Glembatumumab Vedotin|Drug: Phase II: Glembat Squamous Cell Carcinoma of the Lung PrECOG, LLC. 2016-04-10 PHASE1; PHASE2
NCT03473691 WITHDRAWN Drug: Glembatumumab Vedotin Triple Negative Breast Cancer University of Virginia 2018-05-01 EARLY_PHASE1
NCT03326258 WITHDRAWN Drug: Glembatumumab Vedotin Advanced Malignant Solid Neoplasm; Estrogen Receptor Negative; GPNMB Positive; HER2/Neu Negative; Metastatic Malignant Solid Neoplasm; Metastatic Melanoma; Progesterone Receptor Negative; Stage III Breast Cancer AJCC v7; Stage III Cutaneous Melanoma AJCC v7; Stage III Uveal Melanoma AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Breast Cancer AJCC v6 and v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Stage IV Uveal Melanoma AJCC v7; Triple-Negative Breast Carcinoma; Unresectable Solid Neoplasm National Cancer Institute (NCI) 2018-04-20 PHASE1; PHASE2
NCT02487979 COMPLETED Drug: Glembatumumab Vedotin Recurrent Osteosarcoma National Cancer Institute (NCI) 2016-02-16 PHASE2

(data from https://clinicaltrials.gov, updated on 2020-08-21)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.